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What’s known on this subject: Penicillin allergic patients are found to have longer hospital 
stays and increased rates of serious infections secondary to suboptimal antibiotic options 
compared to non-penicillin allergic patients. Fortunately studies have shown that over 90% of 
patients who report penicillin allergy are able to, in fact, tolerate penicillin antibiotics. Patients 
are infrequently evaluated for true or persistence of penicillin allergy. Penicillin skin testing 
followed by oral challenge is a safe way to identify patients who are no longer allergic. 
Providing penicillin skin testing to patients has the potential to improve care by allowing patients 
to receive first line penicillin and penicillin derivative antibiotics if preferred to treat their 
infection. The conversion from broad spectrum antibiotics to penicillin antibiotics is estimated to 
lower health care costs and improve antibiotic usage. 
What This Study Adds: This study describes utilizing a multi-disciplinary team of allergists, 
pharmacists and infectious disease antibiotic stewardship practitioners. The results highlight how 
penicillin allergy evaluations effect antibiotic usage for inpatient’s requiring antimicrobials for 
an acute infectious process benefiting from a penicillin antibiotic despite penicillin allergy on the 
medical record. This study discusses the workflow and collaboration of an interdisciplinary 
inpatient stewardship allergy assessment team program, development of the program, and 
provides guidance for institutions interested in setting up a similar program. 
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Abstract 
Background and Objective: A national urgency to prevent further antibiotic resistance has 
prompted federal funding for antibacterial resistance leadership groups and antimicrobial 
stewardship programs. Penicillin skin testing (PST) is an important addition to these programs as 
skin testing can safely identify patients who are no longer allergic and may receive penicillin. 
Inpatient penicillin allergy evaluations are safe, validated, and will reduce broad spectrum 
antimicrobial use. Patients who are identified as no longer having penicillin allergy will be able 
to transition to first line antimicrobial agents, allowing for targeted antibiotic selection. The 
stewardship allergy assessment team (StAAT) consists of representation from pharmacy, 
infectious disease, and allergy who offer PST and evaluation for inpatients with penicillin 
allergy. This team strives to improve patient care by expanding accessibility to this evaluation.  
Methods: Healthcare providers place consults to the StAAT for inpatients with penicillin 
allergy. Eligible patients receive PST (prick and intradermal) with Pre-PenÒ and Penicillin G; 
those with negative test results receive a supervised oral challenge to amoxicillin. Data related to 
allergy history, indication for consult, test results, changes in antibiotic selection, length of stay, 
and cost are recorded. 
Results: To date, the StAAT has completed 77 penicillin drug allergy evaluations. Indications 
for testing included the following: pneumonia, fever of unknown origin, neurosyphilis, 
bacteremia, bone/joint, urinary tract, intraabdominal, and skin/soft tissue infections. Of these, 73 
(94.8%) were cleared of previous penicillin allergy after negative skin testing and supervised oral 
challenge to amoxicillin. Two patients had positive PST and 2 had an equivocal PST. A total of 
56 (72.7%) patients were started on a penicillin, penicillin derivative, or cephalosporin after 
clearance of their allergy. The use of vancomycin, aztreonam, ciprofloxacin, linezolid, and 
	 6	
cefepime all decreased after the consult and these findings were significant for vancomycin, 
aztreonam, and cefepime. Of the 73 patients who were cleared, all (100%) electronic medical 
records were updated to reflect this updated status.  
Conclusions: A multidisciplinary approach allows for increased accessibility to penicillin 
allergy evaluations for inpatients.  Providing penicillin skin testing for inpatients is safe and 
leads to a reduction in the use of broad spectrum antibiotics.  
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Introduction 
Penicillin allergy is a challenge for both patients and practitioners. Allergy to penicillin 
and derivatives are among the most commonly reported drug allergies with approximately 10% 
of the U.S. population reporting this allergy1.  Clinical studies, however, have suggested that 
90% of this group is able to tolerate penicillin antibiotics1,2.  Additionally when looking 
specifically at inpatients, 15% report a penicillin allergy3-5. It is not common knowledge that 
penicillin allergy can be outgrown or that validated skin testing combined with a supervised oral 
challenge is a safe and definitive way to determine current penicillin allergy status. A negative 
skin prick and intradermal test has a negative predictive value that approaches 100%6,7. 
Completing the final step of testing which is an oral challenge eliminates any prior concerns and 
gives the patient peace of mind that they can tolerate penicillin/penicillin derivatives.  
Approximately 50% of patients can tolerate penicillin if the allergic reaction occurred 
within 5 years; this number approaches 80% when the patient is 10 years past the initial allergic 
reaction 1. There are several reasons patients initially labeled as penicillin allergic may later be 
able to tolerate this drug. First, as the numbers imply above, patients have the ability to lose 
sensitivity if penicillin is avoided after the initial reaction8. Secondly, penicillin allergy is often 
misdiagnosed if a patient develops a rash while taking antibiotics when they have a concurrent 
viral infection as viral infections can also cause viral exanthems and hives9. Additionally, if a 
patient reports an adverse reaction to a penicillin or penicillin derivative such as nausea, 
dizziness, or diarrhea, this entry may be misclassified as an allergy instead of an adverse drug 
reaction and perpetuated in their medical record without re-evaluation. Another scenario 
encountered is when patients report a penicillin allergy when a family member is allergic despite 
the fact that there is not a known inheritance pattern for this allergy. Failure to address penicillin 
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allergy can result in treatment failures and unnecessary broad-spectrum antibiotic use, prompting 
allergy involvement within the realm of antimicrobial stewardship10,11. 
Clarifying penicillin allergy status improves patient outcomes and has the potential to 
improve public health by reducing antibiotic resistance.  Penicillin allergy is considered a public 
health issue since penicillin allergic patients are often prescribed second-line broad spectrum 
antibiotics, which can contribute to overall antibiotic resistance and the creation of 
“superbugs”12. In addition, patients labeled as penicillin allergic have poorer outcomes as noted 
by increased rates of serious infections, and tend to have longer hospital stays when 
admitted10,11,13. Antibiotic resistances as well as infections from broad spectrum antibiotics such 
as clostridium difficile and vancomycin-resistant enterococcus are two such infections that often 
cause problems for penicillin allergic patients12. Additionally, evidence suggests that pregnant 
women with penicillin allergy, with or without group B streptococcus (GBS) infections, have 
higher rates of cesarean sections and spend more days in the hospital14. Although antibiotics 
have changed the practice of medicine and allowed for the treatment of previously untreatable 
diseases, their misuse and overuse has led to resistant bugs that are becoming increasingly 
difficult to treat12. It is therefore important to use the correct and preferred antibiotic whenever 
possible.  
A national urgency has prompted federal funding for antibiotic stewardship leadership 
programs and recently penicillin skin testing has been recommended to augment optimal 
antibiotic use by the National Quality Forum15. Penicillin skin testing augments antibiotic 
stewardship aims by helping to identify patients that are no longer penicillin allergic so that they 
can receive penicillin or a penicillin derivative if this antibiotic is preferred15. Penicillin skin 
testing with PrePenÒ (penicilloyl-poly-lysine) and penicillin G followed by an oral amoxicillin 
	 9	
challenge is a useful and safe approach to evaluate whether a patient’s allergy persists6. 
Additionally, once a patient has had negative skin testing and passed an oral challenge, patients 
are not at increased risk of resensitization after penicillin/derivative use16.  
It is important that healthcare providers are aware of this intervention so that patients who 
are no longer allergic to penicillin have the option to use penicillin and penicillin derivative 
antibiotics when indicated.  Allergists can provide education to patients and healthcare providers 
and advocate for increased accessibility of allergy evaluation to address the public health 
problem of penicillin allergy. Infectious disease providers and pharmacists are key partners in 
addressing drug allergies as each bring their expertise to augment the education that allergists 
provide regarding management of drug allergy. 
Duke University Medical Center has an antibiotic stewardship program in place. In order 
to improve current aims related to optimal antibiotic selection, a collaboration was formed 
between allergy/immunology, infectious disease, and pharmacy to address penicillin allergy. 
StAAT members perform penicillin skin testing and supervised oral challenges to de-label 
patients who have outgrown their penicillin allergy in a safe way. 
Methods 
 In November of 2016, the Stewardship Allergy Assessment Team (StAAT) was 
established at Duke University hospital and consists of a collaboration between 
allergy/immunology, infectious disease, and pharmacy. Initially one allergy/immunology fellow 
and two pharmacists were trained by an allergy nurse in proper skin prick testing and intradermal 
skin prick testing for penicillin allergy. This team has since expanded to include additional 
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allergy/immunology fellows, an infectious disease fellow, and an infectious disease physician 
assistant who underwent appropriate allergy skin testing training.  
Eligible patients are identified for inpatient allergy assessment either by their health care 
provider team or by a pharmacist. Patients are eligible if they would benefit from a penicillin, 
penicillin derivative, or beta-lactam antibiotic during their current admission or in the near 
future. Patients on medications that interfere with the histamine control (which is a standard part 
of skin testing to ensure integrity of mast cells and their ability to release histamine is intact) are 
not eligible for the assessment. Finally, patients have to be at least five years removed from their 
allergic reaction unless discussed with an allergy/immunology attending.  
In terms of process, once the team determines a patient would benefit from skin testing, a 
thorough allergy assessment is completed (see Table 1 for list of questions asked). The 
assessment includes the reaction type, details of the reaction, time since reaction, tolerance of 
other beta-lactams, and a review of current medications. The assessment ensures that the reaction 
reported is not consistent with a delayed hypersensitivity reaction (i.e. Steven’s Johnsons 
Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Acute generalized erythematous pustulosis 
(AGEP), or Drug rash with eosinophilia and systemic symptoms (DRESS), as skin testing is 
contraindicated for these cases. Skin testing cannot identify if a patient will have a delayed 
hypersensitivity reaction and is only useful in identifying whether a patient will experience an 
immediate type 1 hypersensitivity reaction. 
If the patient’s history is consistent with a type 1 hypersensitivity reaction and they agree 
to the full evaluation, the patient is then skin tested. Skin prick testing uses the following 
reagents: Pre-Penâ (major determinant), diluted penicillin G (minor determinant), and standard 
	 11	
controls saline and histamine. Saline is used to control for dermatographism, and histamine is 
used to ensure that the patient’s mast cells are releasing histamine appropriately (and not blunted 
by use of other medications). After skin prick tests are placed, there is a 15 minute wait time 
prior to reading and interpretation of the results. The test is considered positive if there is an area 
of induration or redness 3 mm larger than the saline control for either the Pre-Penâ or Penicillin 
G. If the skin prick test is negative, a total of five intradermal tests are placed. The intradermals 
include Pre-Penâ in duplicate, Penicillin G in duplicate, and saline. The intradermal test is 
considered positive if the intradermal site is 3 mm larger than the saline control after 15 minutes. 
A test is considered equivocal, if the wheal is only slightly larger (2-3 mm) than the initial 
injection bleb and control site, with or without erythematous flare or if the intradermal duplicate 
tests are discordant. 
If both the skin prick and intradermal tests are negative, the patient receives a one-time 
dose of amoxicillin (250 mg) with increased monitoring where vitals are checked every 15 
minutes for the first hour after ingestion. If the patient does not develop any objective findings 
consistent with a type 1 hypersensitivity reaction after their oral challenge with amoxicillin, the 
patient’s penicillin allergy is removed from the electronic medical record and their primary 
health care team is notified. The patient is also advised that they are no longer allergic to 
penicillin and can now safely receive penicillin and penicillin derivative antibiotics. Patients are 
also given a wallet card with their updated penicillin allergy status to share with providers 
outside of Duke’s system and local pharmacists who do not have access to their electronic 
medical record. A team member additionally created an electronic alert notifying providers from 
the StAAT if a penicillin allergy is erroneously re-entered on a patient who is cleared of their 
penicillin allergy.  
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 In addition to providing inpatient evaluations, the allergy department also sought to 
increase access to outpatient penicillin allergy evaluations. This goal was accomplished by 
creating a bi-monthly dedicated penicillin allergy clinic. The clinic is staffed by one registered 
nurse, one allergy/immunology fellow, and one allergy/immunology attending physician; up to 
six patients are scheduled for evaluation during each clinic. The same procedure as the inpatient 
evaluation is implemented with the exception of a two-step graded challenge with amoxicillin 
instead of the one step graded challenge used in the inpatient setting.  Partnerships between 
transplant infectious disease and the perioperative anesthesia clinic are in place in attempts to 
provide this testing pro-actively for patients who would benefit from penicillin/penicillin 
derivative medications. 
 After obtaining IRB approval by Duke University, we collected data from patients who 
were evaluated by the StAAT between November 2016 and February 2017. The data reviewed 
included details related to prior allergy history (see Table 1 for Allergy Assessment 
Questionnaire utilized by StAAT), indication for the consult and penicillin allergy evaluation, 
and antibiotics prescribed pre and post evaluation. Our primary outcome was incident de-
escalation to more narrow spectrum and first line antibiotics. 
Results 
 Data was collected from 77 inpatients evaluated by the StAAT between November 2016 
to February 2018. This cohort does not include patients who were initially evaluated but not able 
to complete skin testing; this may have occurred if patients were unable to mount an appropriate 
histamine control, or if the skin testing was not able to be completed prior to hospital discharge. 
Table 2 includes detailed information regarding patient demographics. Of the 77 patients, 39 
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(50.6%) were female. The majority of patients reported their race as white (n=61, 79.2%) 
followed by 15 patients (19.5%) who were black, and 1 patient (1.3%) who reported being of 
more than 2 races. The age range was from 21 to 92 years. Of note, the highest percentage of our 
patients were in the 65-74 age bracket (n=21, 27.3%) followed by patients who were 75 or older 
(n=17, 22.1%). Additionally, we did not exclude patients who were considered 
immunosuppressed. A total of 8 (10.4%) of the patients tested were transplant patients. Twenty-
one (27.3%) of patients had a history of cancer.  
With regards to allergy history, the majority of patients (n=44, 57.1%) reported a history 
of rash or hives; others reported anaphylaxis (n=17, 22.1%), unknown history (n=11, 14.3%), 
angioedema (n=4, 5.2%), and other (n=1, 1.3 %). The other reaction reported was that the patient 
had an allergic reaction after eating meat that was treated with antibiotics and on a separate 
occasion developed leg swelling after taking a penicillin antibiotic. Figure 1 details the allergic 
reaction reported by patient history. The most common infectious indications evaluated included 
intravascular infection (n=21, 27.3%), urinary tract infection (n=13, 16.9%), intraabdominal 
(n=10, 13.0%), and bone and joint infections (n= 10, 13.0%). Other indications included the 
following: skin and soft tissue infection, pneumonia, central nervous system infection, fever of 
unknown origin, and prophylaxis. Refer to Figure 2 for full details regarding infectious 
indications for testing. 
With regards to skin testing results, the majority of patients (n=73, 94.8%) had negative 
skin testing results. Of these, all 73 completed the supervised oral challenge with 250 mg of 
amoxicillin and tolerated the oral challenge as indicated by lack of an IgE-mediated allergic 
response (hives, swelling, shortness of breath, anaphylaxis). Of the 77 evaluated, two patients 
had equivocal test results and two patients had positive skin test results. The positive and 
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equivocal test results occurred with the intradermal skin testing step. Of the 73 patients cleared 
of their penicillin allergy, one patient experienced an adverse event. The patient had a history of 
both penicillin and cephalosporin allergies. The patient developed a rash after receiving a 
cephalosporin antibiotic despite communication that the testing did not imply clearance of 
cephalosporin allergy in addition to penicillin allergy.  
We reviewed the use of broad spectrum antibiotics including vancomycin, aztreonam, 
ciprofloxacin, linezolid, and cefepime before and after penicillin allergy evaluation consult. 
Refer to Table 3 for full details regarding changes made to a patient’s antibiotic regimen after 
testing. There were reductions in the use of all five of these antibiotics, however, the reduction 
was noted to be significant for cefepime, vancomycin, and aztreonam (p values of 0.02987, < 
0.0001, and < 0.0001, respectively). With regards to antibiotic selection after consults, five 
patients (6.5%) had their antibiotics discontinued, 16 (20.8%) either remained on the same 
regimen or were changed to a non-beta lactam antibiotic, and the majority (n=56, 72.7%) had 
their antibiotics de-escalated to penicillin, a penicillin derivative, or a cephalosporin.  Figure 3 
details these changes. Of the patients who had their antibiotics de-escalated, many patients were 
switched to start a penicillin derivative (n=29, 39.7%), cephalosporin (n=23, 50.0%), and 
penicillin (n=6, 10.3%). See Figure 3 for these changes. 
Discussion 
Given the rise in anti-microbial resistance and the clinical implications associated with 
penicillin allergy, it is critical to identify patients previously labeled as penicillin allergic who 
can safely be treated with penicillin or a penicillin derivative. Our findings demonstrate that 
inpatient penicillin skin testing followed by an oral challenge is feasible, safe and leads to 
changes in antibiotic prescribing. When patients are cleared, providers and patients have more 
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choice in what antibiotic can be prescribed, including first line narrow spectrum antibiotics such 
as penicillin and penicillin derivatives.  
Anti-microbial Changes as a Result of StAAT Consults 
As we expected, providing inpatient consults to evaluate penicillin allergy significantly 
reduced the use of broad-spectrum antibiotics, including vancomycin, aztreonam, and cefepime. 
Most patients tested (72.7%) had their medications switched to an optimal beta-lactam following 
testing. There are some considerations for why all patients who were cleared of their penicillin 
allergy were not transitioned to beta-lactam antibiotics. Possible reasons that explain why a 
patient’s antibiotics were not changed include: the organism was not susceptible to beta-lactam 
antibiotics, provider preference, or an infection was later ruled out for patients who were started 
on empiric therapy. Our findings are consistent with other reports of inpatient penicillin skin 
testing programs that were also able to transition patients who tested negative for penicillin 
allergy to beta-lactam antibiotics5,17,18. The ability of patients to be transitioned to preferred 
antibiotics during their hospitalization likely explains why our team has informally received 
positive feedback from both providers and patients. We plan to measure satisfaction of providers 
and patients in the future to provide data regarding the value of the program from a satisfaction 
standpoint.  
Cost 
While the complete test takes on average 1.5-2 hours, the benefits that follow for a 
patient who is able to be cleared surpass any inconvenience. While limitations are placed on 
antimicrobial choices for penicillin allergic patients and affect a patient’s clinical course, 
penicillin allergy additionally contributes to increased costs for these patients12. Inpatients with 
penicillin allergy tend to have higher antibiotic costs for both medications used during their 
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hospitalization and also for discharge medications19. A study by Macy and Contreras compared 
the cost of skin testing and money saved by shortening hospitalization days for 51,582 patients 
with penicillin allergy13. The cost for testing was $131.37 per test (total of 6.7 million dollars) 
however this testing contributed to a 64 million dollar savings for the three year study period, 
which is a savings that is 9.5 times the cost of the evaluation13. A smaller study that looked at 
cost-effectiveness of penicillin skin testing for fifty patients found an overall cost savings of 
$11,005 ($297 per patient switched to a beta-lactam antibiotic)20. A systematic review completed 
by Mattingly et al. found that outpatient prescriptions cost $14 to $193 more for penicillin 
allergic patients21. Additionally, inpatients without penicillin allergy saved between $1145 to 
$4254 for their inpatient admission21. Not all studies however have found that penicillin skin 
testing results in cost saving. A study by Forrest et al. did not find a difference in antibiotic costs 
for patients with negative penicillin skin testing who were switched to a penicillin antibiotics22.  
Our team plans to complete a cost-analysis as a future project. In reviewing the cost of 
antibiotics at our institution, it is possible that switching off of certain antibiotics such as 
aztreonam ($153.00 a day currently) will show significant cost savings while changing therapy 
from vancomycin to a penicillin/penicillin derivative would not have as large a gain from a cost 
perspective given that the cost of vancomycin is low at $6.24 a day. While a monetary cost from 
changing from vancomycin to a penicillin/penicillin derivative will not be evident, the patient 
can still benefit from avoidance of adverse side effects such as the development of vancomycin-
resistant enterococci, which in turn contributes to increased medical cost through treatment 
failure and complications. It is important to consider indirect costs such as missed work from a 
hospital stay or afterwards during recovery as well as to consider quality of life21. 
	 17	
Continued studies that detail the long term outcomes that penicillin allergy evaluations 
allow for patients through increasing their antibiotic selection options are important. These 
studies and work can help to inform policy so that in the future, it is routine for all hospitals and 
healthcare centers to have the ability to complete allergy evaluations for patients with a history 
of penicillin allergy.   
Implications for Hospital Wide Policy and Further Program Development 
The results from the evaluation of the StAAT imply that penicillin allergy re-evaluation 
should remain a part of the current anti-microbial stewardship initiatives. Initially, patients on 
broad spectrum antibiotics should be prioritized for these evaluations until it is possible to have 
the medical providers available to evaluate all patients with penicillin allergy who present as 
inpatients. Rather than continue a patient on broad spectrum antibiotics, a thorough allergy 
history should be obtained. If the patient has definitely tolerated a penicillin or derivative since 
the allergic reaction (can be confirmed by medical record or history), the medical record should 
be updated and the patient should be switched to a penicillin/penicillin derivative if best option 
to treat their underlying infection. If the history is unknown or the patient has not tolerated the 
medication since allergic reaction, the patient should undergo penicillin skin testing followed by 
a supervised oral test dose to determine whether the allergy persists. 		
Strengths of a Multi-disciplinary Team 
A key strength of the StAAT is the multi-disciplinary participation of team members 
from allergy/immunology, infectious disease, and pharmacy, who each bring their expertise to 
address the problem of penicillin allergy. Pharmacists and infectious disease providers play a key 
role in being the first to identify a patient who could benefit from a penicillin allergy evaluation. 
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They are additionally excellent at providing education regarding why the evaluation will benefit 
their treatment course. Allergists complement antimicrobial stewardship programs as they are 
able to first distinguish whether the reaction that the patient experienced is consistent with an 
IgE-mediated allergic reaction and complete skin testing and interpret the results. In the instance 
that a patient remains allergic to penicillin, allergists can additionally provide the patient with a 
desensitization protocol, which will allow the patient to temporarily tolerate the preferred 
medication. 
Limitations  
This program was implemented at a large academic teaching institution and our results 
may not be generalizable to other institutions.  Allergy specialists are not always available to 
complete drug allergy evaluations at all hospitals5,23. An IDSA survey noted that 60% of 
healthcare providers had penicillin skin testing available at their institution and 90% of this 
testing was performed by allergy/immunology providers24. Additionally, less than 15% of U.S. 
hospitals have the necessary skin testing reagents and materials on formulary5. While the 
penicillin allergy evaluation is ideally completed with allergy involvement, understandably not 
every hospital or clinic has access to an allergist. Lack of personnel and time are two key barriers 
for penicillin skin testing25. For hospitals that do not have an allergy presence, other interested 
services can fill this need after appropriate education and training. Published protocols and 
expert opinion from allergists can be implemented for health care systems that lack access to 
allergy physicians. 
Lessons Learned 
Skin Testing Dilemmas 
 Our team had a number of patients who were pre-screened for medications that would 
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interfere with an appropriate histamine control and despite not taking medications that would 
interfere did not mount an appropriate response. In looking at which patients did not mount 
appropriate histamine responses, many of these patients were in the Intensive Care Unit (ICU). 
Our team now typically will place a histamine before ordering skin testing reagents PrePen® and 
Penicillin G for those patients who are in the ICU or recently came from the ICU to ensure that 
the patient will be able to undergo skin testing that day. Further studies may identify an etiology 
behind whether excessive stress to the body for certain patients (i.e. critical care or surgical) 
effects the ability of their mast cells to release histamine and mount an appropriate histamine 
response for skin testing. 
 Another lesson learned is that inpatients have the potential to have more fragile skin and 
less surface area to complete skin testing because of intravenous lines or bruising. While we 
typically use the volar surface of the arm for both prick and intradermal skin testing, at times 
when skin surface area was limited, we utilized a patient’s back for the skin prick testing and 
then used the volar surface of the patient’s arm for the intradermal testing. Given that inpatient 
skin testing can be more challenging, we also modified our skin testing training for providers on 
the StAAT to include both training at our outpatient allergy clinic and two to three allergy 
provider supervised inpatient skin testing consults prior to sign-off. StAAT members additionally 
always had an allergy/immunology attending on service available to discuss test results and 
management of drug allergy should questions arise.  
Electronic Medical Alert 
 Prior to the start of the inpatient program, an internal chart review was completed that 
identified that allergy chart records were surprisingly not always updated to reflect that a patient 
had passed skin testing and was no longer allergic to penicillin. To address this concern, it is now 
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standard protocol that the allergy chart is updated after each consult and all patients who have 
been cleared have their medical chart updated to reflect this change in allergy status. 
Additionally an inpatient who had completed skin testing had their penicillin allergy erroneously 
re-entered. To prevent re-entry of penicillin allergy when the patient was previously cleared, we 
now have an electronic alert that will notify the provider re-entering the allergy as well as the 
StAAT so that a patient’s allergy is not erroneously re-entered. Chen et al. had a similar 
experience where 16 patients who were cleared had their allergy re-entered and mitigated this 
problem by making an electronic medical record alert18.  Their group additionally calls patients 
2-4 weeks after testing to re-iterate education about allergy clearance18. Our team will consider 
whether it would be beneficial to add phone calls as part of our follow up protocol. Our current 
protocol includes providing education after the skin testing is completed and communicating 
with the patient’s team to emphasize test results and education regarding options available. Using 
technology in creative ways is important so that a patient’s chart correctly reflects updated 
allergy results.  
Future Directions 
 The StAAT is currently working on a cost analysis for the inpatient program. We are 
planning to determine the cost changes for patients who underwent penicillin allergy evaluation 
consults as an inpatient and measure this cost change considering also the cost of the skin testing 
and supervised oral challenge. We additionally will look at hospital days to determine cost 
savings if patients are able to be discharged earlier. Of note, the cost analysis is imperfect as we 
will not be able to account for intangible cost improvements which include patient and provider 
satisfaction, but are also important when determining value of this service. 
Additional steps for our team include continuing to raise awareness of the utility and 
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benefit of re-evaluating prior history of penicillin allergy. Clinicians are not routinely taught drug 
allergy concepts5,26. Allergists can show leadership by providing education and support with 
regards to drug allergy management.  Our allergy/immunology providers are currently involved 
in providing education for residents and fellows with regards to options for the evaluation and 
management of drug allergy. The team has additionally created a patient information pamphlet to 
provide patients with up to date information about penicillin allergy and testing available.  
In order to accommodate a greater number of patients who can be evaluated for penicillin 
allergy, the allergy outpatient clinic added a dedicated penicillin allergy evaluation clinic twice a 
month so that we can take a proactive and preventative approach to evaluating penicillin allergy. 
We currently have partnerships in place between anesthesia and transplant infectious disease so 
that we can accommodate these patients who benefit from knowing their current penicillin 
allergy status prior to surgery or transplant. High-risk patients include but are not limited to 
surgery, transplant, hematology/oncology, and immunosuppressed patients and should receive 
this evaluation, ideally prior to hospitalization, so that they will have better antimicrobial choices 
available to them in the future. 
Conclusions 
Given the rise in anti-microbial resistance and both the clinical implications and 
increased costs associated with penicillin allergy, it is crucial for patients identified as penicillin 
allergic to be offered a penicillin allergy evaluation. Our experience details that healthcare 
providers from different areas in medicine can complement each other and work well together to 
take a preventative and proactive approach in an attempt to increase access to penicillin allergy 
evaluations in the inpatient setting. Tackling the issue of penicillin allergy will continue to 
improve antimicrobial stewardship efforts and should additionally help to decrease antimicrobial 
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resistance indirectly as patients are able to use first line antibiotics. Penicillin skin testing is 
feasible and safe in the inpatient setting.  This service improves patient care by allowing for 
immediate antimicrobial changes and better treatment options for patients who are found to no 
longer be allergic to penicillin. 
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Table 1: Antibiotic Allergy Assessment Questions Asked of Patient/Patient’s Family 
  
Question 
 1. What is/are the name(s) of the medication(s) that you reacted to? 
  
2. How long ago did the reaction occur? 
  
3. Which symptoms were involved in the reaction and what were the characteristics? 
  
     - Skin: rash, hives 
     - Breathing: shortness of breath, wheezing, feeling of "throat closing" 
  
     - Anaphylaxis: rapid onset of itchy rash, throat or face swelling, low blood pressure 
  
     - Gastrointestinal: nausea, vomiting, diarrhea 
  
4. When during the course did the reaction occur? 
     - Immediate (within 1-4 hours) 
     - Delayed (3 days or more) 
  
 5. Why was the medication prescribed? 
  
6. What happened as a result of the allergic reaction? 
  
     - Did patient self-discontinue medication? 
  
     - Did patient have to take Benadryl (diphenhydramine)? 
  
     - Did patient have to use an EpiPen (epinephrine injector)? 
  
     - Did patient need to go to urgent care or the hospital for treatment? 
  
8. Have you tolerated the same or similar medication(s) after the reaction? For similar 
medications this can include: 
     - Augmentin (common for sinus infections) 
     - Keflex (common for dental procedures) 
     - Ceftin (common for UTIs, pneumonia, skin infections) 
     - Omnicef (common for UTIs, pneumonia, skin infections) 
  
 9. Have you had symptoms similar to the allergic reaction without taking any drug treatment 
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Table 2: Demographics 
Gender, n (%) 
Female 39 (50.6%) 
Race, n (%) 
White 61 (79.2%) 
Black 15 (19.5%) 
2+ Races 1 (1.3%) 
Ethnicity, n (%) 
Hispanic 3 (3.9%) 
Age, n (%) 
< 21 1 (1.3%) 
21-34 5 (6.5%) 
35-44 8 (10.4%) 
45-54 10 (13.0%) 
55-64 15 (19.5%) 
65-74 21 (27.3%) 
75+ 17 (22.1%) 
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Figure 1: Allergic Reaction by Patient History 
 
 
 
Figure 2: Indication for Testing 
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Table 3: Antibiotic Selection Pre and Post Consult 
 Pre PST Post PST p-value OR (95% CI) 
Vancomycin 
49 (63.6%) 
 
11 (14.3%) 
 
< 0.0001 
 
0.10 (0.04-0.22) 
 
Aztreonam 
20 (26.0%) 
 
0 (0.0%) 
 
< 0.0001 
 
0.00 (0.00-0.16) 
 
Ciprofloxacin 
11 (14.3%) 
 
4 (5.2%) 
 
0.1004 
 
0.33 (0.07-1.19) 
 
Linezolid 
2 (2.6%) 
 
0 (0.0%) 
 
0.4976 
 
0.00 (0.00-5.31) 
 
Cefepime 
15 (19.5%) 
 
5 (6.5%) 
 
0.02987 
 
0.29 (0.08-0.90) 
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Figure 3: Antibiotic Selection Changes After Consult 
 
 
 
 
 
 
	 	
*** Patients who had their anti-microbial regimen de-escalated were transitioned to either a 
penicillin, penicillin derivative, or cephalosporin antibiotic. Penicillin derivatives that patients 
were transitioned to include: ampicillin, ampicillin-sulbactam, amoxicillin, augmentin, nafcillin, 
piperacillin-tazobactam. 
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Table 4: Antimicrobial Cost Comparison  
Antimicrobial Daily Dose Cost per Day 
Penicillin G Potassium injection 24 million units $34.21 
Ampicillin injection 2 g every 4 hours $14.58 
Ampicillin/Sulbactam injection 3 g every 6 hours $9.04 
Ceftriaxone injection 2 g every 24 hours $2.88 
Cephalexin capsule 500 mg every 8 hours $0.69 
Cefuroxime  tablet 500 mg twice daily $8.85 
Amoxicillin capsule 500 mg every 8 hours $0.36 
Amoxicillin/potassium clavulanate  875 mg/125 mg every 12 hours $1.06 
Broad Spectrum Antimicrobial antibiotics 
Aztreonam 2 grams every 8 hours $153.00 
Ciprofloxacin (IV) 400 mg every 12 hours $4.12 
Ciprofloxacin (PO) 500 mg every 12 hours $0.24 
Cefepime 1 gram every 6 hours $21.48 
Linezolid (IV) 600 mg every 12 hours $80.44 
Linezolid (PO) 600 mg every 12 hours $8.78 
Linezolid (PO Liquid) 600 mg every 12 hours $74.55 
Vancomycin 1 g every 12 hours $6.24 
 
Data obtained from Duke University Hospital Pharmacy Team and the following reference: 
Antimicrobial Stewardship Evaluation Team (ASET) Pricing Comparison Chart. Antimicrobial 
Stewardship and Evaluation Team. https://assets.customid.org/ASET Antimicrobial Pricing 
Comparison Chart July 2017_FINAL_0.pdf. Published July 2017. Accessed April 10, 2018. 
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Appendix I: A Systematic Review of Changes Made to Antibiotic Selection after Inpatient 
Penicillin Testing 
Introduction 
A documented penicillin allergy is associated with a number of adverse outcomes for 
patients including longer hospital stays and increased rates of resistant infections (secondary to 
limited treatment options and the use of broad spectrum antibiotics in lieu of penicillin)5,12,27,28.  
Not all patients with a previously documented penicillin allergy are truly allergic; for example, 
some may be misclassified, and others may have outgrown a reaction1,2. Antibiotic stewardship 
programs that include testing for penicillin allergy in appropriate patients are a promising 
strategy for improving treatment options and reducing rates of resistant infection in populations 
with a documented penicillin allergy27.  The aim of this systematic review is to identify whether 
inpatient consults that address penicillin allergy with penicillin skin testing lead to changes in 
antibiotic treatment management to first line antibiotics. A secondary aim is to also assess the 
percentage of patients who tested negative for penicillin allergy to gain further insight on the 
number of inpatients determined to no longer be allergic to penicillin by skin testing. 
Methods 
With the assistance of an experienced medical research librarian, searches were 
conducted in MEDLINE/PubMed, Embase, and Web of Science to identify literature relevant to 
inpatient programs providing penicillin skin testing for patients listed as having a documented 
penicillin allergy. The search terms included both MeSH and Embase terms, and relevant 
keywords such as penicillins, beta-lactams, allergy, drug hypersensitivity, hospitalization, and 
inpatient. The MEDLINE search was run on March 23rd, 2018 and the Embase and Web of 
Science searches were run on 3/26/2018.  Clinical trials.gov was searched to identify any 
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ongoing studies related to inpatients and penicillin skin testing, however, no eligible studies were 
identified. The key questions, inclusion/exclusion criteria, and search strategy are shown in 
Appendix I, Tables 1-3. 
 Full eligibility criteria are shown in Appendix I, Table 2. Trials and observational study 
designs were eligible for this review. The studies had to pertain to inpatients with penicillin 
allergy who underwent penicillin skin testing during their admission. Studies that included 
outpatients or where the setting was unclear and did not mention inpatients were excluded.  This 
review includes studies that utilized penicillin skin testing with major and minor determinants, 
and followed this testing with an oral challenge if skin testing was negative. The different studies 
did exhibit some variability with regards to number of minor determinants included for the skin 
testing as well as the  type of penicillin/penicillin derivative antibiotic administered for the oral 
challenge. 
This review outlines changes in patient management with regards to antimicrobial choice 
after completion of penicillin skin testing. All titles and abstracts identified in database searches 
were assessed for relevance against the inclusion criteria by one reviewer; for titles and abstracts 
marked as potentially relevant, the full-text article was reviewed for eligibility. For each included 
study, one investigator extracted pertinent information about the methods, populations, 
interventions, comparators, outcomes, timing, settings, and study designs, and rated the quality 
of each study using a modified version of the Risk of Bias In Non-randomized Studies – of 
interventions (ROBINS-I)29. A modified list of questions considered are in Appendix I, Table 4. 
Additional components considered included applicability of findings, magnitude of effects, 
certainty, and significance for clinical/public health.  
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Results 
A total of 4,027 citations were retrieved from all databases. After duplicates were 
removed, 3,284 unique citations were screened by title and abstract. Of these, 98 were marked as 
potentially relevant and reviewed for full-text eligibility. A total of 17 studies met full eligibility 
criteria and were included. Appendix I: Figure 1 shows the article flow diagram and reasons for 
exclusion at the full-text stage.  Clinical trials.gov was searched to identify any ongoing studies 
related to inpatients and penicillin skin testing, however, the current studies did not meet 
inclusion criteria for this systematic review. 	
Across the seventeen included studies, sample size for inpatient cohorts who underwent 
penicillin skin testing ranged from 23 to 4455,17,18,25,30-42. The majority of studies took place in 
the U.S. with the exception of two, which took place in Canada and Australia respectively34,40. 
All studies were limited to adults 18 years of age or older with the exception of one, which 
included a small number of patients (0.8%) younger than 18 years of age17. The majority of 
studies are classified as pre/post studies, and two were cohort studies 35,39. Further details related 
to study design, study setting, and age of participants is included in Appendix I, Table 5.  
Across all included studies, the percentage of patients who had negative penicillin skin 
testing ranged from 84-100% (Appendix I, Table 6). The majority of studies reported completion 
of an oral challenge if penicillin skin testing results were negative; only one study opted to only 
complete an oral challenge if a patient was going to receive a cephalosporin or carbapenem37. 
The majority of patients completed skin testing followed by oral challenge without adverse 
reaction. Three studies noted adverse reactions which included anaphylaxis during oral 
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challenge, allergic reaction during skin testing, and development of a rash after oral 
challenge33,34,38. 
Overall, inpatient penicillin skin testing did lead to a change in antibiotic selection for the 
studies reviewed. Patients were changed to penicillin, penicillin derivatives, or cephalosporins 
after inpatient penicillin skin testing in many cases. The use of vancomycin, aztreonam, and 
fluoroquinolones also decreased. The results from the individual studies are shown in Appendix 
I, Table 7.  
Two studies by Arroliga et al. highlight that ICU inpatients benefit from skin testing as 
both studies showed that ICU inpatients with negative skin testing were transitioned to beta-
lactam antibiotics30,31. Del Real et al. observed antibiotic changes for both ICU patients and 
inpatients, noting that 70.3% of ICU patients were changed to beta-lactam antibiotics compared 
to 57.4% of inpatients17. Blumenthal et al. found that patients who were tested when penicillin 
skin testing was available at their hospital had an increased odds of receiving a penicillin or 
cephalosporin with an adjusted OR of 5.7 (95% CI 2.6-12.5)5. Additionally, more patients during 
the skin testing time period compared to standard of care received a penicillin or cephalosporin 
at the time of discharge (26% vs 16%)5. Trubiano et al. found that patients who underwent an 
allergy evaluation and testing were more likely to be prescribed narrow spectrum antibiotics 
(2.81, 95% CI) and beta-lactam antibiotics (3.54, 95% CI)40.  
All included studies consistently noted increases in the use of beta-lactam antibiotics with 
a percentage of patients transitioned to these antibiotics ranging from 38-100%17,18,25,30-39,41,42. A 
number of studies additionally noted decreased use in broad spectrum antibiotics including 
vancomycin and fluoroquinolones17,18,32,36. For full details and percentages by study, see 
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Appendix I, Table 7. In addition to patients receiving first line antibiotics for their infection, cost 
savings ranged from $7,554.08 to $11,00532,33.  
Discussion 
Inpatient penicillin skin testing is a safe way for patients to re-evaluate prior allergy to 
penicillin. When patients are found to no longer be allergic to penicillin, they are able to take 
penicillin, penicillin derivatives, and cephalosporins. Key limitations for the studies evaluated 
include that these studies are subject to selection bias as the studies typically prioritized patients 
with penicillin allergy who would benefit from switching to a beta-lactam during their current 
inpatient stay or near future. Therefore the percentage of patients switched to beta-lactam 
antibiotics is likely higher than it would be if all inpatients with penicillin allergy were evaluated. 
There additionally is a notable broad range in the percentage of patients who were transitioned to 
a beta-lactam antibiotic (38-100%). While patients were found to no longer have penicillin 
allergy in these studies (range of negative skin test results between 84-100%), many patients may 
have not seen a change in antibiotics either because of physician preference, an infection that 
would not benefit from a beta-lactam, or the patient having already completed empiric therapy 
for a suspected infection. Additionally many of the studies included had a small sample size and 
therefore these results are likely not generalizable and larger studies would help provide 
additional information on this topic. Despite limitations mentioned, this review does show that 
inpatient penicillin skin testing is beneficial and provides patients with the option of receiving a 
first line antibiotic if the patient is able to be cleared successfully of prior penicillin allergy. 
Given the clinical implications and increased costs associated with penicillin allergy, it is 
important for patients identified as penicillin allergic to be offered a penicillin allergy evaluation 
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when possible. Tackling the issue of penicillin allergy with penicillin skin testing will continue 
to improve antimicrobial stewardship efforts and should additionally help to decrease 
antimicrobial resistance as patients are able to use first line antibiotics. Penicillin skin testing is 
feasible and safe in the inpatient setting.  Re-evaluating penicillin allergic patients with penicillin 
skin testing improves patient care by allowing for immediate antimicrobial changes and better 
treatment options for patients who are found to no longer be allergic to penicillin. 
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Appendix I, Table 1: Scope of Review and Key Question 
Key Questions  
1 Among inpatients with penicillin allergy who underwent penicillin skin 
testing, were these patients transitioned to more appropriate beta-lactam 
antibiotics after their penicillin allergy was re-evaluated? 
2 Among inpatients with penicillin allergy who underwent penicillin skin 
testing, how many patients tested negative for penicillin allergy by skin 
testing? 
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Appendix I, Table 2: Study Inclusion and Exclusion Criteria 
Category Inclusion Criteria Exclusion Criteria 
Population Inpatient penicillin allergic patients Inpatients without penicillin 
allergy and all outpatients  
Intervention Underwent penicillin skin testing 
(skin prick and intradermal testing) 
followed by oral challenge  
 
Comparator No comparator necessary however 
can include studies that include 
penicillin allergic patients who did 
not undergo skin testing followed by 
oral challenge 
No comparator  
Outcomes Changes noted in antibiotic selection 
pre and post skin testing/oral 
challenge 
Percent of patients with negative 
penicillin skin testing (found to be no 
longer allergic to penicillin) 
 
 
 
Timing No limits No limits 
Settings Inpatient Outpatient 
Publication 
language 
English  
Admissible 
evidence 
(study design 
and other 
criteria) 
Published in full 
Original research, cross-sectional 
studies, clinical trials, cohort studies, 
case series, case reports, QI 
initiatives with adequate 
measurement methods, systematic 
Reviews  
Studies not published in full, 
qualitative studies, results of 
cognitive interviews, 
nonsystematic reviews, editorials, 
policy or recommendation 
statements, abstracts 
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Appendix I, Table 3: MEDLINE, EMBASE, and Web of Science Search Strategy 
MEDLINE (via PubMed) Search date: 3/23/2018 
#1 "beta-Lactams"[Mesh] OR penicillin*[tiab] OR aminopenicillin*[tiab] OR 
amoxicillin*[tiab] OR ampicillin*[tiab] OR azlocillin*[tiab] OR mezlocillin*[tiab] 
OR piperacillin*[tiab] OR pivampicillin*[tiab] OR talampicillin*[tiab] OR 
augmentin*[tiab] OR unasyn[tiab] OR amoxil[tiab] OR nafcil[tiab] OR 
benzylpenicillin*[tiab] OR amdinocillin*[tiab] OR cyclacillin*[tiab] OR 
methicillin*[tiab] OR nafcillin*[tiab] OR oxacillin*[tiab] OR cloxacillin*[tiab] OR 
dicloxacillin*[tiab] OR floxacillin*[tiab] OR carbenicillin*[tiab] OR 
sulbactam*[tiab] OR ticarcillin*[tiab] OR "β-lactam*"[tiab] OR "beta lactam*"[tiab] 
OR beta-lactam*[tiab] 
207,048 
 
#2 "Drug Hypersensitivity"[Mesh] OR "Skin Tests"[Mesh] OR allerg*[tiab] OR 
hypersensitiv*[tiab] OR skin[tiab] OR puncture[tiab] OR scratch[tiab] OR 
prick[tiab]  OR patch[tiab] OR intradermal[tiab] 
839,125 
#3 "Hospitalization"[Mesh] OR "Inpatients"[Mesh] OR hospitaliz*[tiab] OR 
hospitalis*[tiab] OR inpatient*[tiab] OR "in-patient*"[tiab] OR "hospital 
patient*"[tiab]  
456,011 
 
#4 #1 AND #2 AND #3 1,203 
#5 #4 NOT (Editorial[ptyp] OR Letter[ptyp] OR Case Reports[ptyp] OR 
Comment[ptyp])  
1,072 
#6 #5 NOT (animals[mh] NOT humans[mh]) 1,063 
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EMBASE Search date: 3/26/2018 
#1 'beta lactam'/exp OR 'penicillin derivative'/exp OR 'β-lactam*':ab,ti OR 'beta 
lactam*':ab,ti OR penicillin*:ab,ti OR aminopenicillin*:ab,ti OR amoxicillin*:ab,ti OR 
ampicillin*:ab,ti OR azlocillin*:ab,ti OR mezlocillin*:ab,ti OR piperacillin*:ab,ti OR 
pivampicillin*:ab,ti OR talampicillin*:ab,ti OR augmentin*:ab,ti OR unasyn:ab,ti OR 
amoxil:ab,ti OR nafcil:ab,ti OR benzylpenicillin*:ab,ti OR amdinocillin*:ab,ti OR 
cyclacillin*:ab,ti OR methicillin*:ab,ti OR nafcillin*:ab,ti OR oxacillin*:ab,ti OR 
cloxacillin*:ab,ti OR dicloxacillin*:ab,ti OR floxacillin*:ab,ti OR carbenicillin*:ab,ti 
OR sulbactam*:ab,ti OR ticarcillin*:ab,ti  
386,578 
#2 'drug hypersensitivity'/exp OR 'skin test'/exp OR allerg*:ab,ti OR hypersensitiv*:ab,ti 
OR skin:ab,ti OR puncture:ab,ti OR scratch:ab,ti OR prick:ab,ti OR patch:ab,ti OR 
intradermal:ab,ti 
1,198,495 
#3 'hospitalization'/exp OR 'hospital patient'/exp OR hosptializ*:ab,ti OR hospitalis*:ab,ti 
OR inpatient*:ab,ti OR 'in-patient':ab,ti OR 'in-patients':ab,ti OR 'hospital patient':ab,ti 
OR 'hospital patients':ab,ti 
2,743,817 
#4 #1 AND #2 AND #3 6,202 
#5 #4 AND ([embase]/lim NOT [medline]/lim) 2,408 
#6 #5 NOT ('case report'/exp OR 'case study'/exp OR 'editorial'/exp OR 'letter'/exp OR 
'note'/exp OR [conference abstract]/lim) 
875 
 
Web Science Search date: 3/26/2018 
#1 (penicillin* OR aminopenicillin* OR amoxicillin* OR ampicillin* OR azlocillin* OR 
mezlocillin* OR piperacillin* OR pivampicillin* OR talampicillin* OR augmentin* OR 
unasyn OR amoxil OR nafcil OR benzylpenicillin* OR amdinocillin* OR cyclacillin* OR 
methicillin* OR nafcillin* OR oxacillin* OR cloxacillin* OR dicloxacillin* OR floxacillin* 
OR carbenicillin* OR sulbactam* OR ticarcillin* OR "β-lactam*" OR "beta lactam*" OR 
beta-lactam*) AND TOPIC: (allerg* OR hypersensitiv* OR skin OR puncture OR scratch 
OR prick OR patch OR intradermal) AND TOPIC: (hospitaliz* OR hospitalis* OR 
inpatient* OR "in-patient*" OR "hospital patient*") 
Refined by: LANGUAGES: ( ENGLISH ) 
2089 
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Appendix I, Table 4: Risk Of Bias In Non-randomized Studies - of Interventions (Modified List 
of Questions Considered) 
 
Question  
1 Specify the Review Question 
2 List the confounding domains  
3 List the co-interventions that could be different between intervention groups 
4 Risk of bias judgement  
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Appendix I, Table 5: Study and Patient Characteristics  
 
Study Type of Study Hospital Setting Patient Location Age Mean, y (Range) 
Arroliga et al., 2000 Pre/Post Study Academic ICU 64.6 (41-87) 
Arroliga et al., 2003 Pre/Post Study Academic ICU  NR 
Blumenthal et al., 
2017 
Pre/Post Study Academic Inpatients NR (48-80) 
Chen et al., 2017 Pre/Post Study Academic Inpatients 49.3 (16-87) 
Del Real et al., 2007 Pre/Post Study Academic ICU, inpatients, 
outpatients 
59.4 (NR), 99.2% ≥18 
y & 0.8% < 18 y 
Heil et al., 2016 Pre/Post Study Academic ICU, inpatients NR 
Jones et al., 2017 Pre/Post Study Community Inpatients NR 
King et al., 2016 Pre/Post Study Unknown Inpatients 62 (NR) 
Leis et al., 2017 Pre/Post Study 1 Academic, 2 
Community 
ICU, inpatients 68 (55-83) 
Macy et al., 2004 Cohort Academic Inpatients Cases 63.7 (NR) 
Controls 62.3 (NR) 
Nadarajah et al., 2005 Pre/Post Study Community Inpatients NR 
Ramsey et al., 2017 Pre/Post Study Academic Inpatients 66 (NR) 
Rimawi et al., 2013 Pre/Post Study Academic Inpatients NR, all ≥18 y 
Shannon et al., 2016 Cohort  Community ICU, inpatients Cases 65.3 (NR) 
Controls 68.5 (NR) 
Trubiano et al., 2017 Pre/Post Study 2 tertiary referral 
centers 
Inpatients 59 (47-70) 
Wall et al., 2004 Pre/Post Study Academic Inpatients NR, all ≥18 y 
Warrington et al., 2000 Pre/Post Study Tertiary care 
hospital 
Inpatients 56.2 
Abbreviations: ICU= intensive care unit; NR= not reported 
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Appendix I, Table 6: Percentage of Negative Penicillin Skin Testing Results and Adverse 
Effects 
 
Study Number of Patients 
Skin Tested 
Negative 
PST (%) 
Adverse Effects 
Arroliga et al., 2000 24 95.0% NR 
Arroliga et al., 2003 96 88.5% NR 
Blumenthal et al., 2017 278 100% NR 
Chen et al., 2017 228 97.8% NR 
Del Real et al., 2007 445 (Inpatient = 300, 
ICU = 145) 
88.4% NR 
Heil et al., 2016 76 84.0% NR 
Jones et al., 2017 36 100% NR 
King et al., 2016 50 (Medical and 
Surgical inpatients) 
100% 1 patient with anaphylaxis 
during PO challenge. 98% of 
patients negative for PCN 
allergy considering PST and 
PO challenge. 
Leis et al., 2017 90 94% 1 patient developed a rash after 
switched to beta-lactam 
antibiotic 
Macy et al., 2004 141 94.5% NR 
Nadarajah et al., 2005 101 91.0% NR 
Ramsey et al., 2017 50 94.0% NR 
Rimawi et al., 2013 146 99% 1 patient experienced an 
allergic reaction during PST. 
Shannon et al., 2016 63 89% NR 
Trubiano et al., 2017 110  NR 
Wall et al., 2004 23 95.6% 1 equivocal skin test result. No 
adverse reactions. 
Warrington et al., 2000 53 100% NR 
Abbreviations: ICU= intensive care unit; NR= not reported; PCN= penicillin; PO= oral; PST= penicillin skin test 
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Appendix I, Table 7: Effect of Penicillin Skin Testing on Antimicrobial Selection 
 
Study Effect of PST (% BLA 
post PST) 
Other Effects/Observations 
Arroliga et al., 
2000 
48% ----- 
Arroliga et al., 
2003 
39.5% ----- 
Blumenthal et 
al., 2017 
 
 
72% 
 
Patients in skin testing time period were at increased odd of receiving 
BLA (OR of 5.7 95% CI 2.6-12.5) 
Patients in the PST group were also more likely to receive a PCN or 
cephalosporin antibiotic at discharge compared to SOC period (26% 
vs. 16%; p = 0.18) 
Chen et al., 
2017 
38% Decline in the following medications: vancomycin (33%), clindamycin 
(61%), fluoroquinolones (36%), carbapenems (50%), aztreonam (68%) 
Del Real et al., 
2007 
ICU patients 70.3% 
Inpatients 57.4% 
Decrease in vancomycin, fluoroquinolones, 3rd generation 
cephalosporins, clindamycin, metronidazole, gentamycin 
Heil et al., 
2016 
PCN 55%, 
Cephalosporin 40%, 
Carbapenem 5% 
Report that 80% received more effective therapy, 63% received 
narrower spectrum antibiotics, and 61% received more cost effective 
therapy 
Jones et al., 
2017 
 
75%  
Reduced the use of aztreonam, carbapenems, vancomycin, and other 
broad spectrum antibiotics. Approximated a total cost savings of 
$7554.08.  
King et al., 
2016 
75.5%  Overall cost savings of $11,005 ($297 per patient) 
Leis et al., 
2017 
98.8%  ----- 
Macy et al., 
2004 
PCN 17%, 
Cephalosporins 58.9% 
----- 
Nadarajah et 
al., 2005 
PCN 49%, 
Cephalosporin 48% 
96% Reduction in use of vancomycin, 96% reduction in the use of 
fluoroquinolones 
Ramsey et al., 
2017 
PCN 56%, 1st or 2nd 
generation 
cephalosporin 26%, 3rd 
or 4th generation 
cephalosporin 24% 
Avoided a total of 982 days of a second line antibiotic and at least 23 
hospital days were prevented that would have been used to administer 
antibiotics. 
Rimawi et al., 
2013 
99% tolerated full 
course of BLA 
----- 
Shannon et al., 
2016 
57% Cases in allergy assessment group transitioned to BLA therapy more 
often than controls (57.0% vs. 22.0%). 
Trubiano et 
al., 2017 
----- Patients who underwent allergy testing were more likely to receive 
narrow spectrum BLA (3.54, 95% CI), more likely to receive 
appropriate antibiotics (12.27, 95% CI), and less likely to receive 
restricted antibiotics (0.16).  
Wall et al., 
2004 
PCN or BLA 100% ----- 
Warrington et 
al., 2000 
57% BLA therapy was recommended in 96% but only prescribed to 57%. 
 
Abbreviations: BLA = Beta-lactam antibiotics; ICU = Intensive Care Unit; NR= not reported; PCN = Penicillin; 
PST = Penicillin Skin Testing; SOC = Standard of Care 
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Appendix I, Figure 1: PRISMA Flow Diagram 
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